Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Public authority · Finland
Public authority · Norway
Standards of quality and safety for substances of human origin intended for human application · Monitoring and controlling drug precursors
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Norwegian Medicines Agency · filed 14 Dec 2020 · source
Comments from the Norwegian Medicines Agency on the Inception Impact Assessment for the revision of the Union legislation on blood, tissues and cells The Norwegian Medicines Agency (NOMA) welcomes the possibility to comment on the Commission’s Inception Impact Assessment for the revision of the blood, cell and tissue (BTC) legislation. NOMA acknowledges the need for revision of the BTC legislation.
Finnish Medicines Agency · filed 7 Sept 2022 · source
The Finnish Medicines Agency (Fimea) would like to thank the European Commission for the possibility to comment on the Proposal for a Regulation of the European Parliament and of the Council on standards of quality and safety for substances of human origin intended for human application and repealing Directives 2002/98/EC and 2004/23/EC (hereafter, the SoHO Regulation Proposal).
Finnish Medicines Agency · filed 6 Jun 2023 · source
The proposal to strenghten the regulations in the issue of designer precursors is considered important. Therefore the policy options 3 and 4 are the ones which could result in such strengthening. There still is room however for innovation in how perhaps modify the regulations for industry and users concerning specifically and only the substances without known legitimate uses and therefore leaving the regulations…
Norwegian Medicines Agency · filed 6 Jun 2023 · source
Designer precursors is a problem that the current legislation does not fully cover, so a targeted regulatory approach where the issue of designer precursors is included, is very favourable. Policy options 3 and 4 would create maximum impact. Norway has generic scheduling in the national narcotics regulation and considering a regulatory approach on EU-level where the same is done for precursors is very positive.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.